Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports

J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303-e304. doi: 10.1111/jdv.16527. Epub 2020 Jun 8.

Authors

S Ferrucci¹, M Romagnuolo^{1

2}, L Angileri^{1

2}, E Berti^{1

2}, S Tavecchio^{1

2}

Affiliations

¹ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Physiopathology and Transplantation, Università degli Studi di Milano, Milan, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus / isolation & purification*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / virology
Dermatitis, Atopic / complications
Dermatitis, Atopic / drug therapy*
Female
Humans
Interleukin-4 Receptor alpha Subunit / immunology*
Male
Middle Aged
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / virology
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
Interleukin-4 Receptor alpha Subunit
dupilumab